These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 32609011)

  • 1. Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial.
    Bellomo R; Forni LG; Busse LW; McCurdy MT; Ham KR; Boldt DW; Hästbacka J; Khanna AK; Albertson TE; Tumlin J; Storey K; Handisides D; Tidmarsh GF; Chawla LS; Ostermann M
    Am J Respir Crit Care Med; 2020 Nov; 202(9):1253-1261. PubMed ID: 32609011
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock.
    Bellomo R; Wunderink RG; Szerlip H; English SW; Busse LW; Deane AM; Khanna AK; McCurdy MT; Ostermann M; Young PJ; Handisides DR; Chawla LS; Tidmarsh GF; Albertson TE
    Crit Care; 2020 Feb; 24(1):43. PubMed ID: 32028998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock.
    Leisman DE; Handisides DR; Busse LW; Chappell MC; Chawla LS; Filbin MR; Goldberg MB; Ham KR; Khanna AK; Ostermann M; McCurdy MT; Adams CD; Hodges TN; Bellomo R;
    Crit Care; 2024 Apr; 28(1):130. PubMed ID: 38637829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II for the Treatment of Vasodilatory Shock.
    Khanna A; English SW; Wang XS; Ham K; Tumlin J; Szerlip H; Busse LW; Altaweel L; Albertson TE; Mackey C; McCurdy MT; Boldt DW; Chock S; Young PJ; Krell K; Wunderink RG; Ostermann M; Murugan R; Gong MN; Panwar R; Hästbacka J; Favory R; Venkatesh B; Thompson BT; Bellomo R; Jensen J; Kroll S; Chawla LS; Tidmarsh GF; Deane AM;
    N Engl J Med; 2017 Aug; 377(5):419-430. PubMed ID: 28528561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial.
    Wieruszewski PM; Bellomo R; Busse LW; Ham KR; Zarbock A; Khanna AK; Deane AM; Ostermann M; Wunderink RG; Boldt DW; Kroll S; Greenfeld CR; Hodges T; Chow JH;
    Crit Care; 2023 May; 27(1):175. PubMed ID: 37147690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA Approval of Angiotensin II for the Treatment of Hypotension in Adults with Distributive Shock.
    Senatore F; Jagadeesh G; Rose M; Pillai VC; Hariharan S; Liu Q; McDowell TY; Sapru MK; Southworth MR; Stockbridge N
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):11-20. PubMed ID: 30144016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study.
    Chawla LS; Busse L; Brasha-Mitchell E; Davison D; Honiq J; Alotaibi Z; Seneff MG
    Crit Care; 2014 Oct; 18(5):534. PubMed ID: 25286986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II in Vasodilatory Shock.
    Wakefield BJ; Busse LW; Khanna AK
    Crit Care Clin; 2019 Apr; 35(2):229-245. PubMed ID: 30784606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II in septic shock.
    Jadhav AP; Sadaka FG
    Am J Emerg Med; 2019 Jun; 37(6):1169-1174. PubMed ID: 30935784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the norepinephrine to angiotensin II conversion ratio in patients with vasodilatory hypotension: A post-hoc analysis of the ARAMIS trial.
    See EJ; Chaba A; Spano S; Maeda A; Clapham C; Liu J; Khasin M; Liskaser G; Eastwood G; Bellomo R
    J Crit Care; 2024 Feb; 79():154453. PubMed ID: 37890357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin II and Vasopressin for Vasodilatory Shock: A Critical Appraisal of Catecholamine-Sparing Strategies.
    Heavner MS; McCurdy MT; Mazzeffi MA; Galvagno SM; Tanaka KA; Chow JH
    J Intensive Care Med; 2021 Jun; 36(6):635-645. PubMed ID: 32223515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catecholamine-Sparing Effect of Angiotensin II in an Anephric Patient With Mixed Shock After Cardiac Revascularization Surgery: A Case Report.
    Cutler NS; Khanna AK
    A A Pract; 2020 Jul; 14(9):e01266. PubMed ID: 32909718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Multicenter Observational Cohort Study of Angiotensin II in Shock.
    Smith SE; Newsome AS; Guo Y; Hecht J; McCurdy MT; Mazzeffi MA; Chow JH; Kethireddy S
    J Intensive Care Med; 2022 Jan; 37(1):75-82. PubMed ID: 33231111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shock.
    Leisman DE; Handisides DR; Chawla LS; Albertson TE; Busse LW; Boldt DW; Deane AM; Gong MN; Ham KR; Khanna AK; Ostermann M; McCurdy MT; Thompson BT; Tumlin JS; Adams CD; Hodges TN; Bellomo R
    Ann Intensive Care; 2023 Dec; 13(1):128. PubMed ID: 38103056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Renin-Angiotensin-Aldosterone System Dysfunction With Angiotensin II in High-Renin Septic Shock.
    Chow JH; Wallis M; Lankford AS; Chancer Z; Barth RN; Scalea JR; LaMattina JC; Mazzeffi MA; McCurdy MT
    Semin Cardiothorac Vasc Anesth; 2021 Mar; 25(1):67-73. PubMed ID: 32787515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renin-angiotensin-aldosterone system dynamics after targeted blood pressure control using angiotensin II or norepinephrine in cardiac surgery: mechanistic randomised controlled trial.
    Coulson TG; Miles LF; Zarbock A; Burrell LM; Patel SK; von Groote T; Pilcher D; Weinberg L; Landoni G; Bellomo R
    Br J Anaesth; 2023 Oct; 131(4):664-672. PubMed ID: 37481435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin II Administration in Patients With COVID-19 Shock.
    Ofosu-Barko K; Liu Y; Alkhatib Tamimi F; Al Husami W; Ganatra S; Resnic F; Shah SP
    Crit Pathw Cardiol; 2021 Jun; 20(2):100-102. PubMed ID: 33031192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional differences in the treatment of refractory vasodilatory shock using Angiotensin II in High Output Shock (ATHOS-3) data.
    Abril MK; Khanna AK; Kroll S; McNamara C; Handisides D; Busse LW
    J Crit Care; 2019 Apr; 50():188-194. PubMed ID: 30553989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Angiotensin II in Severe Vasoplegia After Left Pneumonectomy Requiring Cardiopulmonary Bypass: A Renin Response Analysis.
    Trethowan B; Michaud CJ; Fifer S
    Crit Care Med; 2020 Oct; 48(10):e912-e915. PubMed ID: 32931196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of angiotensin II in treatment of refractory distributive shock.
    Rodriguez R; Fernandez EM
    Am J Health Syst Pharm; 2019 Jan; 76(2):101-107. PubMed ID: 31361800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.